序号 |
标题 |
次数 |
作者 |
发布时间 |
80011 |
1201415-84-0,1180007-00-4,DOTA-Lys-Cys-COOH |
98 |
h |
2024-12-11 |
80012 |
CRISPR/Cas9系统基因敲除个别外显子(操作步骤) |
549 |
axc |
2024-12-11 |
80013 |
大环螯合物DOTA,DOTA-RGD |
91 |
h |
2024-12-11 |
80014 |
BocNH-O-(CH₂)₅-COOH BOC 保护基-氨基-五碳链-羧酸 |
162 |
zcy |
2024-12-11 |
80015 |
基因敲除方法,基因敲除小鼠定制服务 |
200 |
axc |
2024-12-11 |
80016 |
"Maleimide-(CH2)5-COONHS cas:55750-63-5 6-(马来酰亚胺基)己酸琥珀酰亚胺酯" |
123 |
zcy |
2024-12-11 |
80017 |
质粒构建的原理、步骤|质粒构建定制服务 |
478 |
axc |
2024-12-11 |
80018 |
DOTA-「Tyr3」-Octreotide,Edotreotide,奥曲肽的多肽 |
144 |
h |
2024-12-11 |
80019 |
Mal-PEG-CH2CO2H(马来酰亚胺) |
125 |
WYQ |
2024-12-11 |
80020 |
Stearic acid-PEG-CH2CO2H |
139 |
WYQ |
2024-12-11 |
80021 |
Dotatate,DOTA-奥曲肽 |
144 |
h |
2024-12-11 |
80022 |
螯合剂多肽DOTA-cyclo(RGDfK) |
120 |
h |
2024-12-11 |
80023 |
Biotin-PEG-CH2CO2H(生物素)(聚乙二醇)(甲基羧酸) |
163 |
WYQ |
2024-12-11 |
80024 |
Pomalidomide-PEG4-CH2COOH (CAS: 2097938-44-6) |
100 |
WYQ |
2024-12-11 |
80025 |
Pomalidomide-PEG2-CH2COOH (CAS: 2143097-05-4) |
109 |
WYQ |
2024-12-11 |
80026 |
Hydroxy-PEG1-CH2-Boc |
120 |
kx |
2024-12-11 |
80027 |
Thalidomide-O-PEG2-CH2-Ald (CAS: 2286368-58-7) |
159 |
WYQ |
2024-12-11 |
80028 |
双功能螯合剂DOTA-多肽;DOTA-cRGD 大环螯合剂修饰靶向环肽 |
118 |
h |
2024-12-11 |
80029 |
DSPE-PEG-CH2COOH(CAS: 474922-20-8) |
147 |
WYQ |
2024-12-11 |
80030 |
质粒构建的过程,制备方法 |
345 |
axc |
2024-12-11 |
80031 |
Tos-PEG1-CH2-Boc的应用和用途 |
161 |
kx |
2024-12-11 |
80032 |
204318-14-9,DOTA-(Tyr3)-octreotate,依多曲肽 |
84 |
h |
2024-12-11 |
80033 |
"Maleimide-(CH2)2-COOH cas:7423-55-4 3-马来酰亚胺基丙酸" |
189 |
zcy |
2024-12-11 |
80034 |
Propargyl-PEG3-CH2CO2H |
150 |
WYQ |
2024-12-11 |
80035 |
DOTA多肽分子探针,619300-53-7 |
130 |
h |
2024-12-11 |
80036 |
t-Boc-Aminooxy-PEG2-CH2CO2tBu(CAS: 2100306-57-6) |
101 |
WYQ |
2024-12-11 |
80037 |
β-NF-CH2-OH |
141 |
kx |
2024-12-11 |
80038 |
PEG5-(CH2CO2t-Butyl)2(CAS: 211746-78-0) |
145 |
WYQ |
2024-12-11 |
80039 |
Hydroxy-PEG4-CH2-Boc |
167 |
kx |
2024-12-11 |
80040 |
PEG6-(CH2CO2t-Butyl)2(CAS: 211746-79-1) |
136 |
WYQ |
2024-12-11 |
80041 |
七肽DOTA-YLYEIAR,1262403-91-7 |
121 |
h |
2024-12-11 |
80042 |
质粒构建的原理与类型 |
176 |
axc |
2024-12-11 |
80043 |
Thalidomide-5-NH2-CH2-COOH |
147 |
kx |
2024-12-11 |
80044 |
Cbz-N-Amido-PEG4-CH2COOH(CAS: 1451362-51-8) |
152 |
WYQ |
2024-12-11 |
80045 |
HO-PEG10-CH2COOtBu |
99 |
|
2024-12-11 |
80046 |
t-butyl ester-PEG4-CH2COOH (CAS: 929087-83-2) |
155 |
WYQ |
2024-12-11 |
80047 |
什么是载体构建与质粒构建 |
231 |
axc |
2024-12-11 |
80048 |
Fmoc-Gly-NH-CH2-acetyloxy |
97 |
kx |
2024-12-11 |
80049 |
Fmoc-N-amido-PEG11-CH2-aldehyde |
144 |
WYQ |
2024-12-11 |
80050 |
PEG4-(CH2CO2tBu)2 (CAS: 132684-09-4) |
153 |
WYQ |
2024-12-11 |
80051 |
Fmoc-PEG4-GGFG-CH2-O-CH2-Cbz |
122 |
kx |
2024-12-11 |
80052 |
CbzNH-PEG3-CH2CH2NH2(CAS: 863973-20-0) |
158 |
WYQ |
2024-12-11 |
80053 |
GGFG-amino-CH2O-acetyl Exetecan(CAS: 1599440-12-6) |
110 |
WYQ |
2024-12-11 |
80054 |
H2N-C6-NH-CO-CH2-O-Ph-CH2-NH-Boc |
99 |
kx |
2024-12-11 |
80055 |
Fmoc-G-amino-CH2O acetyl-Exetecan(CAS: 1599440-09-1) |
126 |
WYQ |
2024-12-11 |